Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Buy
55
CORT Quote, Financials, Valuation and Earnings
Last price:
$58.29
Seasonality move
:
2.99%
Day range:
$57.86 - $60.04
52-week range:
$20.84 - $75.00
Dividend yield:
0%
P/E ratio:
47.03x
P/S ratio:
9.81x
P/B ratio:
9.05x
Volume:
663.5K
Avg. volume:
1.2M
1-year change:
136.5%
Market cap:
$6.2B
Revenue:
$675M
EPS (TTM):
$1.24
Analysts' Opinion
-
Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $99.75, Corcept Therapeutics has an estimated upside of 71.04% from its current price of $58.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $76.00 representing 100% downside risk from its current price of $58.32.
Fair Value
-
According to the consensus of 2 analysts, Corcept Therapeutics has 71.04% upside to fair value with a price target of $99.75 per share.
CORT vs. S&P 500
-
Over the past 5 trading days, Corcept Therapeutics has overperformed the S&P 500 by 1.19% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Corcept Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corcept Therapeutics has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Corcept Therapeutics reported revenues of $181.9M.
Earnings Growth
-
Corcept Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Corcept Therapeutics reported earnings per share of $0.26.
Enterprise value:
5.8B
EV / Invested capital:
8.49x
Price / LTM sales:
9.81x
EV / EBIT:
42.13x
EV / Revenue:
8.55x
PEG ratio (5yr expected):
1.54x
EV / Free cash flow:
29.45x
Price / Operating cash flow:
33.80x
Enterprise value / EBITDA:
41.72x
Gross Profit (TTM):
$664.2M
Return On Assets:
19.52%
Net Income Margin (TTM):
20.92%
Return On Equity:
23.78%
Return On Invested Capital:
23.78%
Operating Margin:
13.89%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $401.9M | $482.4M | $675M | $135.4M | $181.9M | |
| Gross Profit | $396.5M | $475.9M | $664.2M | $133.5M | $178.9M | |
| Operating Income | $112.6M | $107.3M | $137M | $31.7M | $25.3M | |
| EBITDA | $116.1M | $109.6M | $138.3M | $31.9M | $25.7M | |
| Diluted EPS | $0.88 | $0.95 | $1.24 | $0.28 | $0.26 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $478.5M | $266.5M | $499.3M | $458.6M | $471.6M | |
| Total Assets | $571.7M | $423.8M | $583.4M | $621.5M | $840.6M | |
| Current Liabilities | $47.5M | $47.5M | $72.5M | $104.5M | $140.8M | |
| Total Liabilities | $48.4M | $48M | $81.6M | $114.8M | $161M | |
| Total Equity | $523.3M | $375.8M | $501.8M | $506.7M | $679.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $120.3M | $127M | $198.1M | $5.9M | $59.3M | |
| Cash From Investing | -$114.3M | $90.9M | -$177.6M | $17.1M | -$64.4M | |
| Cash From Financing | -$17.3M | -$148.7M | -$28.3M | $766K | -$4.6M | |
| Free Cash Flow | $119.9M | $126.9M | $195.9M | $5.9M | $59.2M | |
CORT
Sector
Market Cap
$6.2B
$39.2M
Price % of 52-Week High
77.76%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
136.5%
-38.63%
Beta (5-Year)
0.612
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$57.80
200-day SMA
Buy
Level
$47.15
Bollinger Bands (100)
Buy
Level
51.42 - 63.88
Chaikin Money Flow
Sell
Level
-350K
20-day SMA
Buy
Level
$57.65
Relative Strength Index (RSI14)
Sell
Level
47.96
ADX Line
Buy
Level
12.03
Williams %R
Neutral
Level
-32.0602
50-day SMA
Sell
Level
$60.95
MACD (12, 26)
Buy
Level
13.03
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
1.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (22.4621)
Buy
CA Score
(Annual)
Level (2.1717)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-4.1026)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Stock Forecast FAQ
In the current month, CORT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CORT average analyst price target in the past 3 months is $99.75.
-
Where Will Corcept Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corcept Therapeutics share price will rise to $99.75 per share over the next 12 months.
-
What Do Analysts Say About Corcept Therapeutics?
Analysts are divided on their view about Corcept Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corcept Therapeutics is a Sell and believe this share price will drop from its current level to $76.00.
-
What Is Corcept Therapeutics's Price Target?
The price target for Corcept Therapeutics over the next 1-year time period is forecast to be $99.75 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CORT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corcept Therapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CORT?
You can purchase shares of Corcept Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corcept Therapeutics shares.
-
What Is The Corcept Therapeutics Share Price Today?
Corcept Therapeutics was last trading at $58.29 per share. This represents the most recent stock quote for Corcept Therapeutics. Yesterday, Corcept Therapeutics closed at $58.32 per share.
-
How To Buy Corcept Therapeutics Stock Online?
In order to purchase Corcept Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 26
Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.
Sell
39
W alert for Mar 26
Wayfair [W] is up 2.01% over the past day.
Sell
46
TSLA alert for Mar 26
Tesla [TSLA] is up 3.5% over the past day.
